This is Berenice Hong, working at EQC27 in Korea. We would like to sell COVID19 Test Kits ( FDA & EUA approved, made by Korea) to extend our business line with you. If you are interested in as a buyer or an introducing broker, please let us know. If you want to have any further inquiry, please reply back. We can do further discussion such as video meetings, sharing brochures of the product that you may need. *COVID19 Detection Kits(* price negotiable) 1. RT-PCR tests (1) Made in Korea (2) Over 1M tests : (3) Over 3M tests : (4) Over 5M tests : (5) EUA(Emergency Use Authorization), CE-IVD 2. Anti-body tests (1) Made in Korea (2) Test result is known within 10 mins. (3) FDA listed : (4) FDA non-listed : 3. Order Process (1) (Buyer) Submit a LOI including potential buyers' name, location, the person in charge, product-type, quantity, etc. (2) (Seller) Provide product's info. (3) (Buyer) Make an payment(T/T). (4) (Seller) Ship the products(EXW).
covid 19 test kit
BIOGENIX SARS CoV2 RT-PCR KIT Only Single Tube Multiplex Real time PCR kit made in India Three times higher throughput than other RT-PCR assays Detects two genes for COVID 19 Screening and Confirmation in single tube NIV-ICMR validated & CDSCO approved
Rapid Malaria pv./pf Test Kit The One Step Malaria (P.f./P.v.) Test is a rapid chromatographic immunoassay for the qualitative detection of plasmodium falciparum Histidine Rich Protein-II (HRP-II) and plasmodium vivax Lactate Dehydrogenase (LDH) in Whole Blood to aid in the diagnosis of Malaria (P.f./P.v.).
We provide GeneFinderTM COVID-19 Plus RealAmp Kit CE-IVD The analysis method, it is a nose testing. (Viral RNA extration menthod) The test results comes out in 120mins (2 hours) which is the most advanced type in the world. 1 Kit = 100 testing Directly with korean manufacturer
Offering COVID-19 test kit here as follows; 1) 1 kit for 100 test cost $3,300 FOB 2) Sample order MOQ = 1 kit plus 800 USD for FEDEX air-shipping. (shipping cost will be vary depend on location) 3) FDA/ CE approved 4) Korean product Detail information will be sent by email if you provide to me. Please consider it and do not hesitate to contact me at any time.
Fully certified to UK standard Covid-19 Test kits.
This is CIF price from China
[Product Name] PE cap for vacutainer evacuated blood collection [Place of Origin] CHINA [Brand Name] DESHENG [Size] For 12*75mm 12*100mm 16*100mm Tube [Model Number] VACUUM TUBE CAP1 [Minimum Order Quantity] 50000pcs [Packaging Details] Carton Box [Color] Red Yellow Blue Green Black White Orange Purple [Validaty Period] 5 Years [Weight] 50kg/10000pcs Vacuum PE Cap Blood Collection Tube Additives And PE Cap Butyl Rubber Compound
MastoCheck is a blood test that can easily screen for breast cancer at an early stage. Breast cancer is diagnosed early by substituting the quantitative values of three types of protein biomarkers in the blood, which are closely related to breast cancer, into a unique, patented algorithm. An innovative and convenient test method that detects early breast cancer with an accuracy of 92% (based on the patent) by using only a very small amount of blood. Bertis has developed multiple markers that can detect early breast cancer with an accuracy of 92% through identification of multiple proteins that are expressed sensitively in early-stage breast cancer and combination of certain proteins that demonstrated high accuracy and reproducibility among these combinations. DEVELOPMENT PROCESS: - MASTOCHECK was developed by a team led by Professor Dong-Young Noh, a world-renowned authority on breast cancer, of Seoul National University. - After analyzing approximately 600,000 proteins and selecting 3 markers exhibiting optimal accuracy, the highest accuracy was obtained by adding Bertis�¢?? own algorithm that enhances accuracy. - After several years of repeated validation work, a medical device product license was obtained from the MFDS in January 2019. To date (as of September 2023), MASTOCHECK has been introduced to about 400 hospitals and screening institutions nationwide, with priority given to large screening institutions.
Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood. High diagnostic accuracy : Quantitative values of biomarkers are measured and entered in a unique algorithm with applied AI. Convenience : No burden of inconvenience caused due to the use of a separate diagnostic device other than blood sampling Efficiency: Provides diagnosis opportunities to more people in situations where personnel and devices are limited
Exo-PASS Exosomes contain proteins, lipids, nucleic acids, and metabolites, and can be easily enriched from biofluids, providing very valuable information for early detection and monitoring of diseases. The Ministry of Food and Drug Safety requires RNA, lipid and proteomic analyses in its guidelines for the development of exosome therapeutics, and PASS provides these analyses in an all-in-one package. Exosome RNA Sequencing: PASS enables rapid and efficient isolation of RNAs and profiling of exosome nucleic acids using qRT-PCR and novel sequencing methods. Exosome Lipidomics: We perform high-reliability and high-sensitivity analysis through an ultra-high-performance tool (UPLC, Orbitrap Exploris 480 MS) and lipid analysis experts who have been producing and interpreting analysis data for many years. Exosome Proteomics: PASS offers and performs quantification analysis that meets customer needs based on the unique expertise in exosome protein extraction. We provide reliable results through deep profiling of exosome proteome and a specialized data library. Our world-class bioinformatics research team at Bertis reviews and interprets pan-omics data (RNA/Lipid) to support in-depth research.
PASS is an analysis solution optimized for academia and pharma research. The proprietary solution was derived from proven technology and innovation embedded in Mastocheck, a proteomics-based early cancer diagnostics approved by Ministry of Food and Drug Safety (MFDS). Bertis developed the PASS solution based on its pan-omics, bioinformatics, and artificial intelligence (AI) technologies. We provide a variety of analyzes for proteomic analysis, biomarker discovery and verification, new drug development, clinical process development, etc. PASS is a platform for integrative analysis of pan-omics data, based on our proven and reliable bioinformatics analysis capabilities. Our team consists of experienced scientists with an extensive track record of research achievements spanning more than a decade in mass spectrometry-based proteomics. Bertis possesses the core expertise and proprietary technology for pan-omics (multi-omics) analysis to provide customized solutions in all fields where omics data analysis is applicable. With PASS, you can leverage Bertis scientific resources and cutting-edge tools to advance your research projects and goals, from the design stage to the interpretation and visualization of bioinformatics analysis results.
Proteomics-based Early diagnosis using multiple markers provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Early diagnostic solutions BERTIS has commercialized MASTOCHECK, the worlds first proteomics-based blood test solution for early diagnosis of breast cancer, and clinical trials are being conducted on biomarkers for various cancers. Ultimately, these technologies are being used to continually expand the pipeline to allow dozens of diseases to be diagnosed with a single blood test.
Biomarker Diseases Diagnosis Blood Tests Proteomics-based early diagnosis Provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Advantages of proteomics-based early diagnosis: Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood.
PC-PASS Protein Characterization Analysis Protein Characterization (Physicochemical property of proteins) structure analysis using mass spectrometry provides results that meet the requirements of the FDA, the MFDS and other regulatory authorities regarding novel therapies or biosimilars. Based on basic amino acid analysis (full sequencing), we perform post-translational modification (PTM) analysis, which is important for protein potency and stability. In this regard, we can perform test methods based on design of experiment (DOE) statistical methodology and deliver documents to be submitted to regulatory authorities. Protein identification and quantification : Structural analysis of all types of protein therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and enzymes - Full Length-Amino acids sequencing Peptide identification of each peak through peptide mapping (MS spectrum confirmation, MS/MS spectral analysis with 100% AA matches) - Improved N- and C-terminal sequencing of proteins Post-translational modification (PTM) : More reliable results based on design of experiment (DOE) statistical methodology to perform the experiments systematically and analyze data efficiently - Disulfide bond analysis ID Total possible lankage analysis - Deamidation identification and quantification - Phosphorylation identification and quantification , phospho-proteomic analysis - Other functional modifications Glycomics : Single protein analysis and research of protein complexes with glycosylation closely related to biological function and toxicity as well as structural stability of proteins - Glycosylation site determination - Glycan profiling - Site-specific glycan identification and quantification - Glycomics research with glycan enrichment
The RPR test is a non-treponemal serological test used to detect antibodies produced in response to Treponema pallidum, the bacterium that causes syphilis. It's a qualitative test, meaning it gives a positive or negative result. The RPR test is typically performed on serum or plasma obtained from a blood sample. In the RPR test, the patient's serum or plasma is mixed with a solution containing cardiolipin, lecithin, and cholesterol particles. If the patient's serum contains antibodies against Treponema pallidum, these antibodies will react with the cardiolipin-lecithin-cholesterol particles, causing visible agglutination or clumping. The RPR card is a specialized card or slide designed to perform the RPR test. It typically contains multiple wells or spots where the serum/plasma sample and the reagent are mixed, allowing for easy observation of agglutination reactions. These cards are convenient for laboratory use, enabling multiple samples to be tested simultaneously and facilitating the interpretation of results.
The RPR test is a non-treponemal serological test used to detect antibodies produced in response to Treponema pallidum, the bacterium that causes syphilis. It's a qualitative test, meaning it gives a positive or negative result. The RPR test is typically performed on serum or plasma obtained from a blood sample. In the RPR test, the patient's serum or plasma is mixed with a solution containing cardiolipin, lecithin, and cholesterol particles. If the patient's serum contains antibodies against Treponema pallidum, these antibodies will react with the cardiolipin-lecithin-cholesterol particles, causing visible agglutination or clumping. A "RPR test slide" could refer to a specialized slide or card used to perform the RPR test. This slide likely contains wells or spots where the serum/plasma sample and the reagent are mixed, allowing for easy observation of agglutination reactions. These test slides are a convenient way to perform the RPR test in a laboratory setting, allowing for multiple samples to be tested simultaneously and facilitating the interpretation of results.
"Factview S. Typhus" may refer to a specific product or brand related to the diagnosis or management of typhus, but without more context, it's challenging to provide precise information. However, I can offer general information about typhus: Types of Typhus: Typhus is a group of infectious diseases caused by different species of bacteria from the genus Rickettsia. The two primary types of typhus that affect humans are epidemic typhus and endemic (murine) typhus. Epidemic Typhus: This type is caused by Rickettsia prowazekii and is transmitted to humans through the bites of infected body lice. Epidemic typhus occurs in outbreaks, often in overcrowded and unsanitary conditions. Endemic (Murine) Typhus: This type is caused by Rickettsia typhi and is transmitted to humans through the bites of infected fleas, typically from rats or other rodents. Endemic typhus is usually milder than epidemic typhus and occurs sporadically in various regions around the world. Symptoms: Symptoms of typhus can vary depending on the type and severity of the infection but often include high fever, headache, rash, muscle aches, and fatigue. Severe cases can lead to complications such as pneumonia, kidney failure, or even death if left untreated. Diagnosis: Diagnosis of typhus typically involves clinical evaluation, including symptoms and medical history, along with laboratory tests such as blood tests to detect antibodies against Rickettsia bacteria or molecular tests to detect the genetic material of the bacteria. Treatment: Typhus is treated with antibiotics, primarily tetracycline or doxycycline, which are effective against Rickettsia bacteria. Prompt treatment is essential to prevent complications and reduce the severity of the illness. Prevention: Preventive measures for typhus include avoiding contact with lice and fleas, practicing good personal hygiene, using insect repellent, and controlling rodent populations in areas where typhus is endemic.
"Factview H. pylori Ab" likely refers to a diagnostic test for detecting antibodies against Helicobacter pylori in biological samples. Helicobacter pylori is a bacterium that colonizes the stomach lining and is associated with various gastrointestinal conditions, including gastritis, peptic ulcers, and even stomach cancer. The "H. pylori Ab" test is designed to identify the presence of antibodies produced by the body in response to H. pylori infection. These antibodies can be detected in serum (blood) samples and serve as markers of past or present H. pylori infection. The test usually involves collecting a blood sample from the patient and then processing it to detect H. pylori antibodies using immunological methods such as enzyme-linked immunosorbent assay (ELISA) or chemiluminescent immunoassay (CLIA). These methods rely on the specific binding of antibodies to H. pylori antigens present in the test kit, leading to a visible or measurable signal indicating the presence of antibodies. Detection of H. pylori antibodies in clinical samples can help confirm H. pylori infection and guide appropriate treatment strategies. However, it's important to note that the presence of antibodies may indicate either current or past infection, as antibodies can persist in the bloodstream for some time after the infection has been cleared. Therefore, additional tests or clinical evaluation may be necessary to determine the timing and severity of the infection.
